Indication
Allergy to House Dust Mites
1 clinical trial
2 products
Clinical trial
A Phase 1 Multiple Ascending Intradermal Dose Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust MitesStatus: Active (not recruiting), Estimated PCD: 2022-12-22
Product
ASP2390Product
Placebo